Antimicrobial Drug Discovery

is an Assistant Professor at the Department of Pathology School of Medicine at the University of New Mexico affiliated with the Center of Molecular Discovery and a Visiting Scientist at the Wellman Center for Photomedicine at Massachusetts General Hospital, Harvard Medical School. He was trained as a molecular microbiologist and received his PhD from the University of Ioannina, Greece. He completed postdoctoral fellowships in Molecular Microbiology (Antimicrobial Discovery Center at Northeastern University, 2001-2003) and Translational therapeutics in Dermatology (Wellman Center for Photomedicine, Harvard Medical School at Massachusetts General Hospital, 2003-2006). His research interests lie in the areas of drug discovery and development of antimicrobial strategies with an emphasis in photodynamic therapy (PDT) for infections and multidrug efflux systems, as well as virulence and microbial pathogenesis. In 1997 he was awarded a European Union Marie Curie Fellowship in Biotechnology, and in 2008 became a founding member of the European Union Cost Action, ATENS, for the reversal of "drug resistance by inhibition of efflux pumps". In the same year he was awarded the Massachusetts Technology Transfer Center (MTTC) Award in Antimicrobials and Biotechnology. Tegos has published 50 peer-reviewed articles, over 50 conference proceedings, book chapters and international abstracts and holds 3 patents. He is also the associate editor for two journals, and recently chaired a session for antifungal drug discovery and repurposing in the 10th Annual Meeting South Central Medical Mycology. Eleftherios Mylonakis is a physician-scientist and his work focuses on the study of microbial pathogenesis and drug discovery. His research has developed a novel alternative to studying bacterial and fungal infection and host responses: the use of invertebrate model hosts. These surrogate invertebrate hosts fill an important niche in fungal pathogenesis research. His investigations have identified novel virulence factors, cross kingdom pathogen-pathogen interactions, novel antifungal agents and evolutionarily conserved traits that are involved in host virulence and immune responses during infection. Recently, Dr. Mylonakis implemented high-throughput whole-animal Caenorhabditis elegans assay to screen libraries of chemical compounds and identify those with antimicrobial activity. In vivo evaluation of libraries of chemical compounds could solve some of the main obstacles in current antifungal discovery, such as finding new classes of compounds and solving the bottleneck of toxicity/efficacy testing. This approach challenges the position that studies in fungal pathogenesis should focus on the analysis of the "host", the "pathogen", or the "antimicrobial compound".Dr. Mylonakis has published over 150 articles in the scientific literature and his studies have been supported by peer-reviewed grants from the National Institutes of Health and private foundations. He is the founding Editor-in-Chief of the journal Virulence and serves on the editorial boards of many publications and as an ad hoc reviewer for over 40 journals.

• 1: Emerging Antimicrobial Drug-discovery Strategies: an Evolving Necessity 2: The Antibiotic Crisis 3: Structure, Genetic Regulation, Physiology and Function of the AcrAB-TolC Efflux Pump of Escherichia coli and Salmonella 4: Small-molecule Efflux Pump Inhibitors from Natural Products as a Potential Source of Antimicrobial Agents 5: Fungal Efflux-mediated Resistance: from Targets to Inhibitors 6: Vacuolar ATPase: a Model Proton Pump for Antifungal Drug Discovery 7: Drug Tolerance, Persister Cells and Drug Discovery 8: Inhibition of Quorum Sensing as a Novel Antimicrobial Strategy 9: Filamentous Temperature-sensitive Mutant Z (FtsZ) Protein as an Antibacterial Target 10: Lysostaphin: a Silver Bullet for Staph 11: Strategies to Identify Modified Ribosomally Synthesized Antimicrobials 12: Quantitative Structure-Activity Relationship-based Discovery of Antimicrobial Peptides Active Against Multidrug-resistant Bacteria 13: Acetyl-CoA Carboxylase as a Target for Antibacterial Development 14: Underexploited Targets in Lipopolysaccharide Biogenesis for the Design of Antibacterials 15: Predicting and Dissecting High-order Molecular Complexity by Information-driven Biomolecular Docking 16: Antifungals and Antifungal Drug Discovery 17: Pathosystematic Studies and the Rational Design of Antifungal Interventions 18: In Vivo High-throughput Antimicrobial Discovery Screens Utilizing Caenorhabditis elegans as an Alternative Host 19: Drosophila melanogaster as a Versatile Model for the Discovery of Drugs Effective against Human Microbe-induced Infection and Pathology 20: Antimicrobial Photosensitizers: Harnessing the Power of Light to Treat Infections 21: Nanoparticle Platforms for Antimicrobial Therapy 22: Antimicrobial Activity of Carbon Nanotubes